Scientific Research and Development
About
The Scientific Research and Development team at Byondis is dedicated to advancing novel treatments for cancers and autoimmune diseases. This multidisciplinary team focuses on pioneering next-generation antibody-drug conjugates (ADCs), creating proprietary linker-drug (LD) technology, and developing site-specific conjugation methods. Their expertise extends to monoclonal antibodies (mAbs) and highly selective small molecules, ensuring precision in disease targeting. This team plays a pivotal role in translating molecular innovations into life-saving therapies with high efficacy and low systemic toxicity.